The structural basis for cancer drug interactions with the catalytic and allosteric sites of SAMHD1
SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase (dNTPase) that depletes cellular dNTPs in noncycling cells to promote genome stability and to inhibit retroviral and herpes viral replication. In addition to being substrates, cellular nucleotides also allosterically regulate SAMHD1 activity. Recently, it was shown that high expression levels of SAMHD1 are also correlated with significantly worse patient responses to nucleotide analog drugs important for treating a variety of cancers, including acute myeloid leukemia (AML). In this study, we used biochemical, structural, and cellular methods to examine the interactions of various cancer drugs with SAMHD1. We found that both the catalytic and the allosteric sites of SAMHD1 are sensitive to sugar modifications of the nucleotide analogs, with the allosteric site being significantly more restrictive. We crystallized cladribine-TP, clofarabine-TP, fludarabine-TP, vidarabine-TP, cytarabine-TP, and gemcitabine-TP in the catalytic pocket of SAMHD1. We found that all of these drugs are substrates of SAMHD1 and that the efficacy of most of these drugs is affected by SAMHD1 activity. Of the nucleotide analogs tested, only cladribine-TP with a deoxyribose sugar efficiently induced the catalytically active SAMHD1 tetramer. Together, these results establish a detailed framework for understanding the substrate specificity and allosteric activation of SAMHD1 with regard to nucleotide analogs, which can be used to improve current cancer and antiviral therapies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:115 |
|---|---|
| Enthalten in: |
Proceedings of the National Academy of Sciences of the United States of America - 115(2018), 43 vom: 23. Okt., Seite E10022-E10031 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Knecht, Kirsten M [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 11.12.2018 Date Revised 13.02.2024 published: Print-Electronic PDB: 6DW4, 6DWD, 6DWK, 6DW3, 6DW5, 6DW7 Citation Status MEDLINE |
|---|
| doi: |
10.1073/pnas.1805593115 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM289404959 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM289404959 | ||
| 003 | DE-627 | ||
| 005 | 20240213232248.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1073/pnas.1805593115 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1290.xml |
| 035 | |a (DE-627)NLM289404959 | ||
| 035 | |a (NLM)30305425 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Knecht, Kirsten M |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The structural basis for cancer drug interactions with the catalytic and allosteric sites of SAMHD1 |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.12.2018 | ||
| 500 | |a Date Revised 13.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a PDB: 6DW4, 6DWD, 6DWK, 6DW3, 6DW5, 6DW7 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase (dNTPase) that depletes cellular dNTPs in noncycling cells to promote genome stability and to inhibit retroviral and herpes viral replication. In addition to being substrates, cellular nucleotides also allosterically regulate SAMHD1 activity. Recently, it was shown that high expression levels of SAMHD1 are also correlated with significantly worse patient responses to nucleotide analog drugs important for treating a variety of cancers, including acute myeloid leukemia (AML). In this study, we used biochemical, structural, and cellular methods to examine the interactions of various cancer drugs with SAMHD1. We found that both the catalytic and the allosteric sites of SAMHD1 are sensitive to sugar modifications of the nucleotide analogs, with the allosteric site being significantly more restrictive. We crystallized cladribine-TP, clofarabine-TP, fludarabine-TP, vidarabine-TP, cytarabine-TP, and gemcitabine-TP in the catalytic pocket of SAMHD1. We found that all of these drugs are substrates of SAMHD1 and that the efficacy of most of these drugs is affected by SAMHD1 activity. Of the nucleotide analogs tested, only cladribine-TP with a deoxyribose sugar efficiently induced the catalytically active SAMHD1 tetramer. Together, these results establish a detailed framework for understanding the substrate specificity and allosteric activation of SAMHD1 with regard to nucleotide analogs, which can be used to improve current cancer and antiviral therapies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Research Support, U.S. Gov't, Non-P.H.S. | |
| 650 | 4 | |a SAMHD1 | |
| 650 | 4 | |a allosteric regulation | |
| 650 | 4 | |a dNTPase | |
| 650 | 4 | |a nucleotide analog drugs | |
| 650 | 4 | |a substrate selection | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Nucleotides |2 NLM | |
| 650 | 7 | |a SAM Domain and HD Domain-Containing Protein 1 |2 NLM | |
| 650 | 7 | |a EC 3.1.5.- |2 NLM | |
| 650 | 7 | |a SAMHD1 protein, human |2 NLM | |
| 650 | 7 | |a EC 3.1.5.- |2 NLM | |
| 700 | 1 | |a Buzovetsky, Olga |e verfasserin |4 aut | |
| 700 | 1 | |a Schneider, Constanze |e verfasserin |4 aut | |
| 700 | 1 | |a Thomas, Dominique |e verfasserin |4 aut | |
| 700 | 1 | |a Srikanth, Vishok |e verfasserin |4 aut | |
| 700 | 1 | |a Kaderali, Lars |e verfasserin |4 aut | |
| 700 | 1 | |a Tofoleanu, Florentina |e verfasserin |4 aut | |
| 700 | 1 | |a Reiss, Krystle |e verfasserin |4 aut | |
| 700 | 1 | |a Ferreirós, Nerea |e verfasserin |4 aut | |
| 700 | 1 | |a Geisslinger, Gerd |e verfasserin |4 aut | |
| 700 | 1 | |a Batista, Victor S |e verfasserin |4 aut | |
| 700 | 1 | |a Ji, Xiaoyun |e verfasserin |4 aut | |
| 700 | 1 | |a Cinatl, Jindrich |c Jr |e verfasserin |4 aut | |
| 700 | 1 | |a Keppler, Oliver T |e verfasserin |4 aut | |
| 700 | 1 | |a Xiong, Yong |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Proceedings of the National Academy of Sciences of the United States of America |d 1915 |g 115(2018), 43 vom: 23. Okt., Seite E10022-E10031 |w (DE-627)NLM000008982 |x 1091-6490 |7 nnns |
| 773 | 1 | 8 | |g volume:115 |g year:2018 |g number:43 |g day:23 |g month:10 |g pages:E10022-E10031 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1073/pnas.1805593115 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 115 |j 2018 |e 43 |b 23 |c 10 |h E10022-E10031 | ||